1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Pugh, D.J.R.
Ab, E.
Faro, A.
Lutya, P.T.
Hoffmann, E.
Rees, D.J.G.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
Bmc Struct.Biol.
1472-6807
6
1
10.1186/1472-6807-6-1
16396680
Dwnn, a Novel Ubiquitin-Like Domain, Implicates Rbbp6 in Mrna Processing and Ubiquitin-Like Pathways
2006
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
N-TERMINAL 5 RESIDUES ARE ARTIFACTS OF THE PGEX-6P-2 CLONING VECTOR
9544.000
RETINOBLASTOMA-BINDING PROTEIN 6, ISOFORM 3
DWNN, RESIDUES 1-81
1
man
polymer
RBBP6
no
no
GPLGSMSCVHYKFSSKLNYDTVTFDGLHISLCDLKKQIMGREKLKAADCDLQITNAQTKEEYTDDNALIPKNSSVIVRRI
PIGGVK
GPLGSMSCVHYKFSSKLNYDTVTFDGLHISLCDLKKQIMGREKLKAADCDLQITNAQTKEEYTDDNALIPKNSSVIVRRI
PIGGVK
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
HUMAN
sample
9606
HOMO SAPIENS
511693
ESCHERICHIA COLI
BL21
(DE3) PLYSS
PGEX-6P-2
repository
Initial release
Version format compliance
Version format compliance
1
0
2006-01-19
1
1
2011-05-08
1
2
2011-07-13
PDBE
Y
PDBE
2005-11-24
REL
THE STRUCTURE WAS DETERMINED USING TRIPLE-RESONANCE NMR SPECTROSCOPY ON A 15N,13C-LABELLED SAMPLE.
LOWEST ENERGY
100
25
HNCO
CBCACONH
CBCANH
HCCH-TOCSY
HCCH-COSY
HNH- HSQC-TOCSY
HNH-HSQC-NOESY
HCH-HSQC-NOESY
HH-NOESY
HMQC-J
HN-EXCHANGE
HH- NOESY
150
mM
6.0
pH
298.0
K
THE FINAL SET OF NOE-BASED RESTRAINTS, TOGETHER WITH DIHEDRAL RESTRAINTS FOR 90 RESIDUES, WERE USED FOR REFINEMENT IN EXPLICIT SOLVENT USING CNS, ACCORDING TO THE STANDARD RECOORD PROTOCOL.
AUTOMATED NOE ASSIGNMENT USING CANDID
18
95% WATER/5% D2O
BRUNGER,ADAMS,CLORE,DELANO,GROS, GROSSE- KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU,READ, RICE,SIMONSON,WARREN
refinement
CNS
1.1
structure solution
NMRVIEW
structure solution
CANDID
structure solution
CYANA
structure solution
CNS
structure solution
RECOORD
600
Varian
INOVA
GLY
1
n
1
GLY
1
A
PRO
2
n
2
PRO
2
A
LEU
3
n
3
LEU
3
A
GLY
4
n
4
GLY
4
A
SER
5
n
5
SER
5
A
MET
6
n
6
MET
6
A
SER
7
n
7
SER
7
A
CYS
8
n
8
CYS
8
A
VAL
9
n
9
VAL
9
A
HIS
10
n
10
HIS
10
A
TYR
11
n
11
TYR
11
A
LYS
12
n
12
LYS
12
A
PHE
13
n
13
PHE
13
A
SER
14
n
14
SER
14
A
SER
15
n
15
SER
15
A
LYS
16
n
16
LYS
16
A
LEU
17
n
17
LEU
17
A
ASN
18
n
18
ASN
18
A
TYR
19
n
19
TYR
19
A
ASP
20
n
20
ASP
20
A
THR
21
n
21
THR
21
A
VAL
22
n
22
VAL
22
A
THR
23
n
23
THR
23
A
PHE
24
n
24
PHE
24
A
ASP
25
n
25
ASP
25
A
GLY
26
n
26
GLY
26
A
LEU
27
n
27
LEU
27
A
HIS
28
n
28
HIS
28
A
ILE
29
n
29
ILE
29
A
SER
30
n
30
SER
30
A
LEU
31
n
31
LEU
31
A
CYS
32
n
32
CYS
32
A
ASP
33
n
33
ASP
33
A
LEU
34
n
34
LEU
34
A
LYS
35
n
35
LYS
35
A
LYS
36
n
36
LYS
36
A
GLN
37
n
37
GLN
37
A
ILE
38
n
38
ILE
38
A
MET
39
n
39
MET
39
A
GLY
40
n
40
GLY
40
A
ARG
41
n
41
ARG
41
A
GLU
42
n
42
GLU
42
A
LYS
43
n
43
LYS
43
A
LEU
44
n
44
LEU
44
A
LYS
45
n
45
LYS
45
A
ALA
46
n
46
ALA
46
A
ALA
47
n
47
ALA
47
A
ASP
48
n
48
ASP
48
A
CYS
49
n
49
CYS
49
A
ASP
50
n
50
ASP
50
A
LEU
51
n
51
LEU
51
A
GLN
52
n
52
GLN
52
A
ILE
53
n
53
ILE
53
A
THR
54
n
54
THR
54
A
ASN
55
n
55
ASN
55
A
ALA
56
n
56
ALA
56
A
GLN
57
n
57
GLN
57
A
THR
58
n
58
THR
58
A
LYS
59
n
59
LYS
59
A
GLU
60
n
60
GLU
60
A
GLU
61
n
61
GLU
61
A
TYR
62
n
62
TYR
62
A
THR
63
n
63
THR
63
A
ASP
64
n
64
ASP
64
A
ASP
65
n
65
ASP
65
A
ASN
66
n
66
ASN
66
A
ALA
67
n
67
ALA
67
A
LEU
68
n
68
LEU
68
A
ILE
69
n
69
ILE
69
A
PRO
70
n
70
PRO
70
A
LYS
71
n
71
LYS
71
A
ASN
72
n
72
ASN
72
A
SER
73
n
73
SER
73
A
SER
74
n
74
SER
74
A
VAL
75
n
75
VAL
75
A
ILE
76
n
76
ILE
76
A
VAL
77
n
77
VAL
77
A
ARG
78
n
78
ARG
78
A
ARG
79
n
79
ARG
79
A
ILE
80
n
80
ILE
80
A
PRO
81
n
81
PRO
81
A
ILE
82
n
82
ILE
82
A
GLY
83
n
83
GLY
83
A
GLY
84
n
84
GLY
84
A
VAL
85
n
85
VAL
85
A
LYS
86
n
86
LYS
86
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
PHE
24
A
N
PHE
24
A
O
SER
7
A
O
SER
7
A
N
LYS
12
A
N
LYS
12
A
O
VAL
75
A
O
VAL
75
A
N
ILE
80
A
N
ILE
80
A
O
ASP
50
A
O
ASP
50
A
N
ILE
53
A
N
ILE
53
A
O
TYR
62
A
O
TYR
62
A
N
ILE
29
A
N
ILE
29
A
O
ILE
69
A
O
ILE
69
2
A
A
OD2
HG
ASP
CYS
48
49
1.54
2
A
A
OD2
HH21
ASP
ARG
48
79
1.60
5
A
A
OD1
HD21
ASP
ASN
64
66
1.58
6
A
A
OD1
HD21
ASP
ASN
64
66
1.59
7
A
A
OD1
HD21
ASP
ASN
64
66
1.59
9
A
A
HZ3
OE1
LYS
GLU
16
42
1.58
9
A
A
OD1
HD21
ASP
ASN
64
66
1.58
10
A
A
HZ3
OE2
LYS
GLU
16
42
1.58
11
A
A
HZ2
OD2
LYS
ASP
35
65
1.54
14
A
A
OD1
HD21
ASP
ASN
64
66
1.58
14
A
A
HZ2
OE2
LYS
GLU
16
42
1.59
18
A
A
OD1
HD21
ASP
ASN
64
66
1.60
20
A
A
OD2
HD21
ASP
ASN
64
66
1.59
22
A
A
HZ2
OD2
LYS
ASP
35
65
1.60
24
A
A
OD1
HD21
ASP
ASN
64
66
1.57
25
A
A
HZ3
OE2
LYS
GLU
16
42
1.59
4
A
ARG
79
0.090
SIDE CHAIN
14
A
ARG
41
0.076
SIDE CHAIN
20
A
ARG
41
0.117
SIDE CHAIN
1
A
LEU
27
-152.58
-41.08
1
A
LYS
43
77.75
72.30
2
A
PRO
2
-93.95
-157.01
3
A
LEU
27
-148.50
-41.32
5
A
MET
6
64.25
-170.87
5
A
LEU
17
74.04
-52.78
5
A
LYS
43
60.75
70.93
7
A
SER
5
57.47
80.45
7
A
LEU
17
73.65
-51.78
7
A
LYS
43
80.40
70.14
8
A
MET
6
55.94
98.67
8
A
LYS
16
-177.81
-39.23
8
A
LEU
17
76.71
-52.53
8
A
LYS
43
71.75
45.02
10
A
PRO
2
-82.57
41.86
10
A
LEU
27
-140.90
-45.75
10
A
ASP
48
-130.23
-40.84
11
A
LEU
27
-145.02
-42.45
11
A
ASP
48
-133.36
-47.20
12
A
PRO
2
-76.54
47.84
12
A
SER
5
-165.87
-62.03
12
A
ASP
48
-130.57
-45.19
13
A
LYS
43
75.37
65.63
14
A
MET
6
60.20
-164.13
15
A
MET
6
63.96
173.73
16
A
SER
5
-149.62
24.03
16
A
MET
6
58.85
113.13
16
A
LYS
43
66.93
66.96
16
A
THR
63
74.41
-36.80
17
A
LYS
43
66.22
68.50
19
A
LYS
43
71.71
62.29
20
A
LEU
27
-131.48
-45.23
20
A
LYS
43
67.35
68.23
21
A
PRO
2
-67.53
-70.76
21
A
SER
5
-144.83
35.47
21
A
LYS
43
71.21
65.92
22
A
LEU
3
69.76
-82.73
22
A
LEU
27
-149.14
-41.11
24
A
SER
5
62.53
85.31
24
A
LEU
17
71.89
-47.31
24
A
LYS
43
76.66
67.06
25
A
LYS
43
61.27
66.13
RETINOBLASTOMA-BINDING PROTEIN 6, ISOFORM 3
Solution NMR structure of the DWNN domain from human RBBP6
1
N
N
A
LEU
31
A
LEU
31
HELX_P
A
LYS
43
A
LYS
43
1
1
13
UBIQUITIN-LIKE PROTEIN
RBBP6, P53-ASSOCIATED, MRNA PROCESSING, SPLICING-ASSOCIATED, OESOPHAGEAL CANCER, UBIQUITIN-LIKE PROTEIN
2C7H
PDB
1
2C7H
Q8N0V2_HUMAN
UNP
1
Q8N0V2
1
5
2C7H
1
5
2C7H
A
1
1
5
1
81
2C7H
6
86
Q8N0V2
A
2
6
86
5
2
anti-parallel
parallel
anti-parallel
anti-parallel
anti-parallel
A
TYR
19
A
TYR
19
A
PHE
24
A
PHE
24
A
SER
7
A
SER
7
A
PHE
13
A
PHE
13
A
VAL
75
A
VAL
75
A
PRO
81
A
PRO
81
A
CYS
49
A
CYS
49
A
ASN
55
A
ASN
55
A
GLU
61
A
GLU
61
A
TYR
62
A
TYR
62
A
HIS
28
A
HIS
28
A
SER
30
A
SER
30
A
LEU
68
A
LEU
68
A
PRO
70
A
PRO
70
1
P 1